this was from the MSN article a while back.
"Coleman Lannum, biotech and medical devices analyst at Putnam Investments, says he believes Biogen has some "potential blockbusters" in its pipeline worth "conservatively" hundreds of millions of dollars, but those products are at least a couple of years away from commercialization. Once a product passes through phase 1, 2 and 3 trials, it can then file an application with the FDA, which will approve or reject a drug for use by patients in the U.S.
...Amevive, a protein that inhibits T-cell function, is in phase 2 trials for psoriasis. It is expected to come to market in the first half of 2002 with a (world) market potential of $3.6 billion, according to Rauch..."
I would offer my guess that the potential for the BGEN drug is over $1B, but, as you know, it usually takes years to develop the market potential of a new drug. My guess is that ML sees the potential in years 2-4 after launch as (conservatively) $300-500 in the US market alone.
|
